Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
PartnerLondon, United Kingdom
Rotem Shani has completed an IPO
Rotem Shani Ltd has completed an IPO to refinance and develop the company.Learn more
Dutch Dental Group has raised new acquisition debt from ING Bank to support its growth strategy
Dutch Dental Group (DDG) has raised a new debt financing package provided by ING Bank, consisting of term loans, an acquisition facility and an RCF.Learn more
Groupe Voie Lactée has been acquired by Initiative & Finance
JFC Industrie has sold Groupe Voie Lactée to Initiative & Finance.Learn more